A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient

A durable response after the discontinuation of immune checkpoint-inhibitor therapy has previously been reported in several cancers. We herein describe a patient with gastric cancer who maintained a durable response after the discontinuation of nivolumab. A 65-year-old man was treated with nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Yatsuda, Yukino, Hirose, Suguru, Ito, Yoshimi, Onoda, Tsubasa, Sugiyama, Yutaro, Nagafuchi, Miho, Suzuki, Hirosumi, Niisato, Yusuke, Tange, Yoshitaka, Ikeda, Takafumi, Yamada, Takeshi, Yamamoto, Yoshiyuki, Ohyama Osawa, Mariko, Sakamoto, Noriaki, Moriwaki, Toshikazu, Mizokami, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079905/
https://www.ncbi.nlm.nih.gov/pubmed/33162479
http://dx.doi.org/10.2169/internalmedicine.5893-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079905/
https://www.ncbi.nlm.nih.gov/pubmed/33162479
http://dx.doi.org/10.2169/internalmedicine.5893-20

Ejemplares similares